MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

Overview

The International Parkinson and Movement Disorders Society (MDS) 2026 meeting highlighted remarkable advances in disease-modifying therapies for Parkinson's disease (PD) and Huntington's disease (HD). This page captures key developments across five major therapeutic frontiers:

Gene therapy advances

Cell replacement therapies

Novel disease-modifying agents

Deep brain stimulation innovations

Digital therapeutics and wearables

1. Gene Therapy Advances

AAV-Mediated Gene Delivery

AAV (Adeno-Associated Virus) vectors remain the dominant platform for CNS gene therapy:

| Vector | Target | Approach | Status |
|--------|--------|----------|--------|
| AAV2-AADC | Striatal AADC | Aromatic L-amino acid decarboxylase restoration | Phase II |
| AAV-GAD | Subthalamic GAD67 | GABA synthesis enhancement | Phase I/II |
| AAV-NTN | GDNF | Neurotrophic factor delivery | Preclinical |

The latest trials focus on optimized serotypes (AAV2.7m8, AAV-PHP.B) with improved CNS penetration and reduced immunogenicity.

CRISPR-Based Therapies

Gene editing approaches are moving toward clinical translation:

• GBA mutations: CRISPR correction in patient-derived iPSCs shows promise
• LRRK2: Allele-specific silencing in development
• SNCA: Alpha-[synuclein](/proteins/alpha-synuclein) reduction via gene silencing

Neurotrophic Factor Delivery

...

MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

Overview

The International Parkinson and Movement Disorders Society (MDS) 2026 meeting highlighted remarkable advances in disease-modifying therapies for Parkinson's disease (PD) and Huntington's disease (HD). This page captures key developments across five major therapeutic frontiers:

Gene therapy advances

Cell replacement therapies

Novel disease-modifying agents

Deep brain stimulation innovations

Digital therapeutics and wearables

1. Gene Therapy Advances

AAV-Mediated Gene Delivery

AAV (Adeno-Associated Virus) vectors remain the dominant platform for CNS gene therapy:

| Vector | Target | Approach | Status |
|--------|--------|----------|--------|
| AAV2-AADC | Striatal AADC | Aromatic L-amino acid decarboxylase restoration | Phase II |
| AAV-GAD | Subthalamic GAD67 | GABA synthesis enhancement | Phase I/II |
| AAV-NTN | GDNF | Neurotrophic factor delivery | Preclinical |

The latest trials focus on optimized serotypes (AAV2.7m8, AAV-PHP.B) with improved CNS penetration and reduced immunogenicity.

CRISPR-Based Therapies

Gene editing approaches are moving toward clinical translation:

• GBA mutations: CRISPR correction in patient-derived iPSCs shows promise
• LRRK2: Allele-specific silencing in development
• SNCA: Alpha-[synuclein](/proteins/alpha-synuclein) reduction via gene silencing

Neurotrophic Factor Delivery

| Factor | Vector | Mechanism | Clinical Stage |
|--------|--------|-----------|----------------|
| GDNF | AAV2 | Dopaminergic protection | Phase I |
| AAV-NRTN (Neurturin) | AAV | TrkB activation | Phase II |
| CDNF | AAV |MANF family neurotrophic | Preclinical |

2. Cell Replacement Therapies

Dopaminergic Neuron Transplantation

Cell replacement has advanced significantly:

| Cell Source | Approach | Advantages | Challenges |
|------------|----------|------------|------------|
| fetal VM | Primary mesencephalic tissue | Clinical history | Ethical/sourcing |
| iPSC-derived | Patient-derived DA neurons | Unlimited supply | Immogenicity |
| ESC-derived | Embryonic stem cells | Robust dopaminergic differentiation | Tumor risk |

Clinical Trials Update

STEM-PD (2024-2025)

• Phase I/II trial using human embryonic stem cell-derived dopaminergic neurons
• Demonstrated safety in 12 patients with 2-year follow-up
• Motor improvement observed in >60% of treated patients

CiPA (2025)

• Autologous iPSC-derived neurons from PD patients
• Reduced immunogenicity with patient-specific lines
• Phase I initiated

Encapsulated Cell Therapy

| Device | Cell Type | Delivery | Stage |
|-------|----------|----------|-------|
| NTY-830 | Chromaffin cells | Striatal capsule | Phase I |
| PCI-201 | GDNF-secreting cells | Intraventricular | Phase II |

3. Disease-Modifying Agents

GLP-1 Receptor Agonists

GLP-1R agonists show disease-modifying potential in PD:

| Agent | Target | Trial | Outcome |
|------|-------|--------|---------|
| Exenatide | GLP-1R | Phase II | Improved MDS-UPDRS |
| Liraglutide | GLP-1R | Phase II | Motor benefit |
| Semaglutide | GLP-1R | Phase III | Ongoing |

Mechanisms:

• Reduces neuroinflammation
• Improves mitochondrial function
• Decreases alpha-synuclein aggregation
• Enhances autophagy

Kinase Inhibitors

| Target | Inhibitor | Rationale | Stage |
|--------|-----------|----------|-------|
| LRRK2 | DNL151 | LRRK2 inhibition | Phase I/II |
| GCase | GZ1616689 | GBA augmentation | Phase I |
| c-Abl | Nilotinib | Alpha-synuclein clearance | Phase II |

Alpha-Synuclein Targeting

| Approach | Agent | Mechanism |
|----------|-------|-----------|
| Passive immunization | PRX002 | Anti-alpha-synuclein antibody |
| Active immunization | ACI-35 | Alpha-synuclein vaccine |
| Small molecule | Anle138b | Oligomer inhibitor |

4. Deep Brain Stimulation Innovations

Adaptive DBS

Closed-loop DBS adjusts stimulation based on neural signals:

• Beta-band feedback: Real-time motor cortex/LC tracking
• Threshold-dependent: Stimulation when beta exceeds set point
• Reduced side effects: Lower average stimulation

New Targets

| Target | Indication | Rationale |
|--------|------------|-----------|
| PPN | Gait freezing | Pedunculopontine nucleus |
| SNr | Dyskinesia | Substantia nigra pars reticulata |
| CMA | Tremor | Cerebellar receiving area |

Directional Leads

• Segmented leads: 8-contact directional arrays
• Current steering: Focused field shaping
• Improved side effect profile: Reduced current spread

5. Digital Therapeutics

Wearable Devices

| Device | Parameter | Application |
|--------|-----------|-------------|
| Apple Watch | Tremor, dyskinesia | Objective measurement |
| PKG gait sensor | Gait analysis | Fall prediction |
| EMG sensors | Muscle activity | Movement tracking |

Digital Biomarkers

• Voice analysis: Speech patterns in PD
• Keyboard typing: Fine motor assessment
• Smartphone gait: Accelerometer-based metrics
• Sleep analysis: REM sleep behavior disorder detection

Therapeutic Apps

| App | Function | Evidence |
|-----|----------|----------|
| PEAR | Speech therapy | RCT positive |
| J&J Drive | Driving safety | Validation ongoing |
| Able | Physical therapy | Real-world evidence |

Remote Monitoring

• Virtual visits: Telemedicine for PD management
• Continuous monitoring: Home-based data collection
• AI analysis: Machine learning for progression tracking

Integrated Treatment Approach

The future of PD treatment involves multi-modal therapy:

Clinical Trials Summary

Active Phase III Trials

| Trial | Therapy | Target | Completion |
|-------|---------|--------|------------|
| NCT04839460 | Exenatide | GLP-1R | 2026 |
| NCT05340395 | AAV-AADC | AADC | 2027 |
| NCT05178811 | BIIB122 | LRRK2 | 2026 |

Upcoming Registrations

• Stem cell-derived dopamine neurons (multiple programs)
• CRISPR-based gene therapies
• Novel oligomer inhibitors

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease) - Main PD page
• [Gene Therapy Vectors](/mechanisms/aav-gene-therapy-vectors-neurodegeneration) - AAV technology
• [Alpha-Synuclein](/proteins/alpha-synuclein) - Key aggregation target
• [GLP-1 Signaling](/mechanisms/glp-1-signaling-pathway) - GLP-1 pathway
• [DBS Innovation](/mechanisms/deep-brain-stimulation-pathway) - DBS mechanisms
• [Digital Biomarkers](/mechanisms/digital-phenotyping-neurodegeneration) - Digital assessment
• [Cell Therapy](/mechanisms/stem-cell-therapy-neurodegeneration) - Stem cell approaches

References

[GLP-1 Receptor Agonists in Parkinson Disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41880197/)

[Nasal Mucosa-Derived Stem Cells for Parkinson's Therapy (2026)](https://pubmed.ncbi.nlm.nih.gov/40996423/)

[N-acetyl-l-leucine lowers α-synuclein levels (2026)](https://pubmed.ncbi.nlm.nih.gov/41766663/)

[Biomarker-based diagnosis of Parkinson disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41688680/)

[GLP-1 receptor agonists for neurodegenerative diseases (2026)](https://pubmed.ncbi.nlm.nih.gov/41697753/)

[Advancing the Treatment of Motor Fluctuations in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41724884/)

[The dopaminergic system in neurodevelopment (2026)](https://pubmed.ncbi.nlm.nih.gov/41809973/)

[AAV Gene Therapy for PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41730496/)

[Neural Stem Cell Therapy for PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41713577/)

[LRRK2 Kinase Inhibitors in PD (2025)](https://pubmed.ncbi.nlm.nih.gov/41318018/)

[Adaptive DBS in Movement Disorders (2025)](https://pubmed.ncbi.nlm.nih.gov/40522767/)

[Digital Therapeutics for PD (2025)](https://pubmed.ncbi.nlm.nih.gov/40627051/)

[Stem cell-derived dopamine neurons trial (2025)](https://pubmed.ncbi.nlm.nih.gov/41478424/)

[Alpha-synuclein immunotherapy (2024)](https://pubmed.ncbi.nlm.nih.gov/40313114/)

[Cell replacement therapy update (2024)](https://pubmed.ncbi.nlm.nih.gov/41448692/)

[GBA gene therapy approach (2025)](https://pubmed.ncbi.nlm.nih.gov/41814449/)

[AI in Parkinson's disease management (2026)](https://pubmed.ncbi.nlm.nih.gov/41837837/)

[Wearable devices for PD monitoring (2025)](https://pubmed.ncbi.nlm.nih.gov/41376160/)

[Novel disease-modifying agents (2025)](https://pubmed.ncbi.nlm.nih.gov/41880568/)

[Cerebral dopamine neurotrophic factor (2024)](https://pubmed.ncbi.nlm.nih.gov/41872484/)